TABLE 1
FROM:
Biotechnology in Cuba: 20 years of scientific, social and economic progress
Ernesto López Mola, Ricardo Silva, Boris Acevedo, José A Buxadó, Angel Aguilera and Luis Herrera
BACK TO ARTICLETable 1. The CIGB's current R&D pipeline
| Project | Discovery | Preclinical | Phase I | Phase II | Phase III | Approval |
|---|---|---|---|---|---|---|
| Hepatitis B without thiomersal | X | X | X | X | X | 2001 |
| G-CSF | X | X | X | X | X | 2002 |
| H. influenzae type b vaccine (Hib) | X | X | X | X | X | 2003 |
| IFN liquid without albumin | X | X | X | X | X | 2003 |
| IFN lyophilised without albumin | X | X | X | X | X | 2003 |
| IFN+ribavirina | X | X | X | X | X | 2003 |
| streptokinase without albumin | X | X | X | X | X | 2003 |
| DPT-HB | X | X | X | X | X | 2004 |
| Erythropoietin | X | X | X | X | X | 2004 |
| DPT-HB+Hib | X | X | X | X | X | 2006 |
| Citoprot-P | X | X | X | X | X | 2006 |
| Hepatitis A vaccine | X | X | X | X | X | 2006 |
| IFN colirium | X | X | X | X | X | 2006 |
| HB-Hib vaccine | X | X | X | X | 2007 | |
| DPT-HB-Hib vaccine | X | X | X | X | 2007 | |
| DPT+Hib vaccine | X | X | X | X | 2007 | |
| Hebervis | X | X | X | X | 2007 | |
| HA+HB vaccine | X | X | X | X | 2007 | |
| IFN gel | X | X | X | X | 2007 | |
| VEGF gene therapy | X | X | X | X | 2007 | |
| Therapeutic HBV vaccine | X | X | X | |||
| Therapeutic HBV/NASVAC | X | X | X | |||
| CIGB-300 | X | X | X | |||
| CIGB-240 | X | X | X | |||
| Conjugate vaccine PS-C:P64k | X | X | X | |||
| Prostate cancer vaccine | X | X | ||||
| Dengue vaccine | X | X | ||||
| AIDS vaccine CR3 | X | X | ||||
| Meningitis vaccine | X | X | ||||
| HPV vaccine | X | X | ||||
| Therapeutic HCV | X | X | ||||
| CIGB-370 | X | X | ||||
| CEA diabody fragment | X | X | ||||
| Antiangiogenic vaccine | X | |||||
| Vaccine IL-15 RA | X | |||||
| Autoimmunity AR | X | |||||
| Antivirals – dengue | X | |||||
| Post-EDL – HIV targets | X | |||||
| Antivirals – HIV | X | |||||
| Neuroregeneration | X | |||||
| Genomics | X |
CEA=anti-carcinoembryonic antigen; CIGB=Center for Genetic Engineering and Biotechnology; DPT=diphtheria; G-CSF=granulocyte colony-stimulating factor; HA=hepatitis A; HB=hepatitis B; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; IFN=interferon; IL=interleukin; HPV=human papilloma virus; NASVAC=a nasal vaccine candidate for chronic hepatitis B immunotherapy; VEGF=vascular endothelial growth factor.
